The US Food and Drug Administration (FDA) has provisionally approved an experimental personalized treatment for a young woman with ALS. The therapy, known as an antisense oligonucleotide (ASO), is designed to disable mutated strands of genetic code to prevent them from producing a protein that causes neurological damage. Click here for the full article
